Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at HC Wainwright

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $32.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 70.85% from the stock’s previous close.

KURA has been the topic of a number of other research reports. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Wednesday, February 28th. Finally, JMP Securities lifted their price objective on shares of Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a research note on Wednesday, January 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.28.

Kura Oncology Trading Up 3.0 %

Shares of KURA stock opened at $18.73 on Monday. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -9.00 and a beta of 0.85. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The firm’s 50 day moving average price is $20.73 and its two-hundred day moving average price is $15.35.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.01. During the same quarter in the previous year, the business posted ($0.49) EPS. On average, analysts anticipate that Kura Oncology will post -2.35 EPS for the current year.

Insider Buying and Selling

In related news, COO Kathleen Ford sold 1,496 shares of Kura Oncology stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $26,628.80. Following the completion of the sale, the chief operating officer now owns 21,602 shares in the company, valued at $384,515.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Kura Oncology news, SVP Thomas James Doyle sold 2,318 shares of Kura Oncology stock in a transaction on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $41,260.40. Following the completion of the transaction, the senior vice president now owns 48,093 shares of the company’s stock, valued at $856,055.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Kathleen Ford sold 1,496 shares of Kura Oncology stock in a transaction on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the completion of the transaction, the chief operating officer now directly owns 21,602 shares of the company’s stock, valued at approximately $384,515.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,867 shares of company stock worth $104,433. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in the business. 1492 Capital Management LLC boosted its holdings in Kura Oncology by 1.0% in the fourth quarter. 1492 Capital Management LLC now owns 101,500 shares of the company’s stock worth $1,460,000 after purchasing an additional 1,034 shares during the period. E Fund Management Co. Ltd. boosted its holdings in Kura Oncology by 12.2% in the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock worth $109,000 after purchasing an additional 1,301 shares during the period. Arizona State Retirement System boosted its holdings in shares of Kura Oncology by 9.8% during the third quarter. Arizona State Retirement System now owns 15,823 shares of the company’s stock valued at $144,000 after acquiring an additional 1,406 shares during the period. Signaturefd LLC boosted its holdings in shares of Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after acquiring an additional 1,449 shares during the period. Finally, Teacher Retirement System of Texas boosted its holdings in shares of Kura Oncology by 11.1% during the third quarter. Teacher Retirement System of Texas now owns 15,490 shares of the company’s stock valued at $141,000 after acquiring an additional 1,544 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.